PMX 53

Drug Profile

PMX 53

Alternative Names: Hydrocinnamate analogues - Promics; PMX53

Latest Information Update: 09 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peptech; The University of Queensland
  • Developer Arana Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Peptides
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Osteoarthritis
  • Discontinued Age-related macular degeneration; Burns; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 09 Mar 2011 No development reported - Preclinical for Osteoarthritis in Australia (PO)
  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
  • 19 Feb 2009 Discontinued - Phase-I for Age-related macular degeneration in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top